Last Updated: November 4, 2026

ZOLPIDEM Drug Patent Profile

Name: ZOLPIDEM Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Zolpidem, and what generic alternatives are available?

Zolpidem is a drug marketed by Almatica, Umedica Labs Pvt, Actavis Elizabeth, Actavis Labs Fl Inc, Apotex, Breckenridge, Lupin, Ph Health, Sandoz, Sun Pharm, Synthon Pharms, Acme Labs, Apotex Inc, Aurobindo Pharma, Chartwell Molecular, Hikma, Invagen Pharms, Mylan Pharms Inc, Rising, Senores Pharms, Strides Pharma, Strides Pharma Intl, Sun Pharm Inds Inc, Sun Pharm Inds Ltd, Sun Pharm Industries, Teva, Torrent Pharms, Watson Labs, Wockhardt, Yung Shin Pharm, Dr Reddys, Novel Labs Inc, and Pharmobedient. and is included in thirty-seven NDAs.

The generic ingredient in ZOLPIDEM is zolpidem tartrate. There is one drug master file entry for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the zolpidem tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zolpidem

A generic version of ZOLPIDEM was approved as zolpidem tartrate by ACME LABS on April 23^rd, 2007.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for ZOLPIDEM?
What are the global sales for ZOLPIDEM?
What is Average Wholesale Price for ZOLPIDEM?

Summary for ZOLPIDEM

US Patents:	0
Applicants:	33
NDAs:	37
Drug Prices:	Drug price information for ZOLPIDEM
Drug Sales Revenues:	Drug sales revenues for ZOLPIDEM
DailyMed Link:	ZOLPIDEM at DailyMed

Drug patent expirations by year for ZOLPIDEM

US Patents and Regulatory Information for ZOLPIDEM

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	ZOLPIDEM TARTRATE	zolpidem tartrate	TABLET;SUBLINGUAL	202657-002	Aug 8, 2016		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Strides Pharma	ZOLPIDEM TARTRATE	zolpidem tartrate	TABLET;ORAL	076062-001	Apr 23, 2007		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Invagen Pharms	ZOLPIDEM TARTRATE	zolpidem tartrate	TABLET;ORAL	078184-002	Sep 7, 2007		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

DrugChatter Q&A for ZOLPIDEM

Cost of zolpidem tartrate 10 mg?
Aceso laboratories zolpidem 510(k)?
Mylan zolpidem?
Zolpidem discount?
Zolpidem price in india 2026?

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.